Tender for the Operating Lease of Biological Atomic Force Microscopy (bioAFM)
Swansea University · Awarded
- Buyer
- Swansea University
- Status
- Awarded
- Country
- United Kingdom
- Region
- England
- Sector
- Manufacturing
- Reference
- FaT-ocds-h6vhtk-029974
- Published
- 2021-03-08
Tender summary
The Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6 million GBP project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is aimed at developing new therapeutics for the treatment of ovarian cancer. A key output of the CEAT project is to establish a developmental pipeline for bioAFM applications in clinically acceptable in vitro and ex-vivo disease models, providing molecular, cellular and tissue level morphological, topographical and biomechanical information to support epigenomic…
This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.
Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.
Register for full access